Navigation Links
Diasome Pharmaceuticals, Inc. and Lyfebulb LLC Announce Partnership
Date:3/15/2016

Diasome Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing novel, cell targeted therapies for treating diabetes and obesity, and Lyfebulb, LLC, a patient-centric organization with a mission to improve the quality of life for people with chronic disease founded by Karin Hehenberger, MD, PhD, CEO Lyfebulb, Stephen Squinto, PhD, co-founder Alexion, and Riccardo Braglia, CEO Helsinn Healthcare, announced today that they have entered into a collaborative agreement to research and develop Diasome’s proprietary liver targeting nanotechnology systems for improving insulin therapy in people with Type 1 and Type 2 diabetes.

Remarking about this new collaboration, Dr. Hehenberger, Lyfebulb’s Chief Executive Officer, said, “We are excited about Diasome’s late-stage clinical technologies that are designed for the improvement of liver glucose metabolism. This technology has the potential to improve the safety and efficacy of insulin therapy for people with diabetes. We are looking forward to assisting Diasome’s business and scientific teams as these therapies advance in the clinic.” Robert Geho, Diasome’s Chief Executive Officer, stated, “Dr. Hehenberger and her team represent some of the most respected voices in diabetes care and therapeutic development, and they are ideal partners for our projects. Because our companies share the common goal of dramatically changing the manner in which the global problem of diabetes is addressed, this partnership will further strengthen our presence in the diabetes community.”

About Lyfebulb:

Lyfebulb is a patient-centric organization whose mission is to improve the quality of life for people living with chronic disease now. Lyfebulb was founded by Dr. Karin Hehenberger, CEO of Lyfebulb, Riccardo Braglia, CEO of Helsinn Healthcare, and Dr. Stephen Squinto, co-founder of Alexion. The Lyfebulb strategy involves partnering with companies aligned with its Mission, growing its online community and creating a powerful event series featuring innovative companies and raising awareness for specific conditions. The Lyfebulb community aims to connect people with chronic disease, inspire them with lifestyle advice and ultimately impact them through its influence on the overall chronic disease and wellness industry. Lyfebulb consulting directly works with select companies that share our vision. For more information, please visit http://www.lyfebulb.com.

About Diasome:

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity. For more information, please visit http://www.diasome.com.

Read the full story at http://www.prweb.com/releases/2016/03/prweb13266652.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Diasome Pharmaceuticals, Inc. Announces Issuance of Oral Insulin Patent by the US PTO
2. Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin
3. Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration
4. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
5. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
6. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
7. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
8. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
9. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
10. Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
11. PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... ... October 08, 2019 , ... As Keck ... Leslie Maurer presented company executives with a set of recommendations to enhance supply ... offer insights from their TMP to a wider audience of industry leaders attending ...
(Date:10/3/2019)... ... 02, 2019 , ... Today marked the official launch of ... program outsourcing success by cultivating radical improvements in leadership, staff, and broader project ... Reese, phaseUP™ brings clients deep, broad and unique expertise in the intricacies of ...
(Date:9/30/2019)... WOODLANDS, Texas (PRWEB) , ... September 30, 2019 ... ... , the materials science newsletter from Rigaku Corporation , is now available ... techniques related to X-ray based materials science, including X-ray diffraction, fluorescence and imaging, ...
(Date:9/24/2019)... WASHINGTON (PRWEB) , ... September 24, 2019 , ... ... addition of Hannah Holscher, PhD, RD, to its Scientific Advisory Board. Dr. Holscher ... Human Nutrition and the Division of Nutritional Sciences at the University of Illinois ...
Breaking Biology Technology:
(Date:10/10/2019)... ... October 09, 2019 , ... Cardea is excited to ... CRISPR-Chip™. Cardea first broke the news of the proposed merger in ... Sensor™. Built with CRISPR-Chip technology, the Genome Sensor is the world’s first DNA ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... new apps that make it easier than ever for businesses and organizations to ... new Countdown App enables organizations to count down to or count up from ...
(Date:10/4/2019)... ... October 03, 2019 , ... Mount Sinai researchers have discovered how ... from one generation to the next. In a study published in Nature Structural & ... this enzyme, leading to cancers and other diseases. , “DNA polymerase delta serves as ...
Breaking Biology News(10 mins):